Tumor Immunoediting and Immunosculpting Pathways to Cancer Progression

Overview

Journal Semin Cancer Biol

Specialty Oncology

Date 2007 Jul 31

PMID 17662614

Citations 78

Authors

Jennifer M Reiman

Maciej Kmieciak

Masoud H Manjili

Keith L Knutson

Affiliations

Soon will be listed here.

Abstract

Recent studies have suggested that a natural function of the immune system is to respond and destroy aberrant, dysfunctional cells by a process called immunosurveillance. These studies also suggest that the tumors that arise despite immunosurveillance have been immunosculpted by the immune system. The purported abilities of tumors to induce immune tolerance and suppression, the increased pathogenic behavior of the tumor cells following exposure to immune effectors and the loss of immunogenicity (i.e. immunoediting) often observed in advanced stage tumors could be the result of immunosculpting. In some cases, these immunosculpting features may be permanent and irreversible. However, in other cases, reversible epigenetic mechanisms may underlie the immune resistant tumor phenotype. Regardless, these immune-induced alterations could contribute to cancer pathogenesis. Understanding the mechanisms by which tumors evade immunity will be important for disease prevention and therapeutics.

Citing Articles

Evodiamine inhibits programmed cell death ligand 1 expression via the PI3K/AKT signaling pathway to regulate antitumor immunity in melanoma.

Li J, Jiang L, Ma Q, Zhang Z, Zheng S, Qiu J Sci Rep. 2025; 15(1):6649.

PMID: 39994441 PMC: 11850830. DOI: 10.1038/s41598-025-91137-2.

Cancer vaccines: an update on recent achievements and prospects for cancer therapy.

Chekaoui A, Garofalo M, Gad B, Staniszewska M, Chiaro J, Pancer K Clin Exp Med. 2024; 25(1):24.

PMID: 39720956 PMC: 11669620. DOI: 10.1007/s10238-024-01541-7.

Targeting Group 3 Medulloblastoma by the Anti-PRUNE-1 and Anti-LSD1/KDM1A Epigenetic Molecules.

Bibbo F, Asadzadeh F, Boccia A, Sorice C, Bianco O, Sacca C Int J Mol Sci. 2024; 25(7).

PMID: 38612726 PMC: 11011515. DOI: 10.3390/ijms25073917.

The role of programmed death receptor (PD-)1/PD-ligand (L)1 in periodontitis and cancer.

Groeger S, Meyle J Periodontol 2000. 2024; 96(1):150-169.

PMID: 38351432 PMC: 11579837. DOI: 10.1111/prd.12548.

What happens to regulatory T cells in multiple myeloma.

Chen H, Wang X, Wang Y, Chang X Cell Death Discov. 2023; 9(1):468.

PMID: 38129374 PMC: 10739837. DOI: 10.1038/s41420-023-01765-8.

References

Knutson K, Disis M, Salazar L . CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother. 2006; 56(3):271-85. PMC: 11030088. DOI: 10.1007/s00262-006-0194-y. View

Kremer K, Kumar A, Hedin K . Haplotype-independent costimulation of IL-10 secretion by SDF-1/CXCL12 proceeds via AP-1 binding to the human IL-10 promoter. J Immunol. 2007; 178(3):1581-8. PMC: 2905171. DOI: 10.4049/jimmunol.178.3.1581. View

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

Vial T, Descotes J . Immunosuppressive drugs and cancer. Toxicology. 2003; 185(3):229-40. DOI: 10.1016/s0300-483x(02)00612-1. View

Butterfield L, Ribas A, Dissette V, Amarnani S, Vu H, Oseguera D . Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res. 2003; 9(3):998-1008. View

Seril D, Liao J, Yang G, Yang C . Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis. 2003; 24(3):353-62. DOI: 10.1093/carcin/24.3.353. View

Cabrera C, Jimenez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F . Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens. 2003; 61(3):211-9. DOI: 10.1034/j.1399-0039.2003.00020.x. View

Baldi A, Battista T, De Luca A, Santini D, Rossiello L, Baldi F . Identification of genes down-regulated during melanoma progression: a cDNA array study. Exp Dermatol. 2003; 12(2):213-8. DOI: 10.1034/j.1600-0625.2003.00026.x. View

Smyth M, Crowe N, Godfrey D . NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol. 2001; 13(4):459-63. DOI: 10.1093/intimm/13.4.459. View

10.

Shankaran V, Ikeda H, Bruce A, White J, Swanson P, Old L . IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001; 410(6832):1107-11. DOI: 10.1038/35074122. View

11.

Foran J, Norton A, Micallef I, Taussig D, Amess J, Rohatiner A . Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol. 2001; 114(4):881-3. DOI: 10.1046/j.1365-2141.2001.03019.x. View

12.

Girardi M, Oppenheim D, Steele C, Lewis J, Glusac E, Filler R . Regulation of cutaneous malignancy by gammadelta T cells. Science. 2001; 294(5542):605-9. DOI: 10.1126/science.1063916. View

13.

Zou W, Machelon V, Borvak J, Nome F, Isaeva T, Wei S . Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med. 2001; 7(12):1339-46. DOI: 10.1038/nm1201-1339. View

14.

Disis M, Gooley T, Rinn K, Davis D, Piepkorn M, Cheever M . Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 2002; 20(11):2624-32. DOI: 10.1200/JCO.2002.06.171. View

15.

Takeda K, Smyth M, Cretney E, Hayakawa Y, Yamaguchi N, Yagita H . Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol. 2002; 214(2):194-200. DOI: 10.1006/cimm.2001.1896. View

16.

Vainio S, Lin Y . Coordinating early kidney development: lessons from gene targeting. Nat Rev Genet. 2002; 3(7):533-43. DOI: 10.1038/nrg842. View

17.

Lejeune F . Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest. 2002; 110(4):433-5. PMC: 150423. DOI: 10.1172/JCI16493. View

18.

Yee C, Thompson J, Byrd D, Riddell S, Roche P, Celis E . Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002; 99(25):16168-73. PMC: 138583. DOI: 10.1073/pnas.242600099. View

19.

Cabrera T, Collado A, Fernandez M, Ferron A, Sancho J, Ruiz-Cabello F . High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens. 1998; 52(2):114-23. DOI: 10.1111/j.1399-0039.1998.tb02274.x. View

20.

Pollard J . Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4(1):71-8. DOI: 10.1038/nrc1256. View